This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Müller, V. Articles by Knabbe, C. Search for Related Content PubMed Articles by Müller, V. Articles by Knabbe, C.

Partial Antagonism between Steroidal and Nonsteroidal Antiestrogens in Human Breast Cancer Cell Lines¹

Department of Clinical Chemistry, University Hospital Eppendorf, D-20246 Hamburg [V. M., C. K.], and Institute for Hormone and Fertility Research, D-22529 Hamburg [E. V. J.], Germany

Nonsteroidal antiestrogens, such as tamoxifen, are well established in the treatment of breast cancer. The development of new steroidal compounds without partial agonist activity allows deeper insights into the mechanism of antiestrogen action, but thus far, the combined use of steroidal and nonsteroidal antiestrogens has not been studied extensively. We compared the nonsteroidal 4-trans-hydroxytamoxifen (OHT) with the two steroidal antiestrogens, ICI 182780 and RU 58668, in the estrogen receptor-positive human breast cancer cell lines MCF-7 and T47D. The effect of each compound alone or of OHT in combination with one of the steroidal antiestrogens was studied in regard to cell proliferation, expression of estrogen receptors (ERs) and progesterone receptors, and secretion of transforming growth factor ß2 (TGF-ß2). All antiestrogens examined led to enhanced secretion of TGF-ß2, which is correlated with their individual growth-inhibitory potential. OHT partially counteracts the larger growth inhibition of human breast cancer cells exerted by the steroidal antiestrogens ICI 182780 and RU 58668. Also, OHT antagonizes the higher induction of TGF-ß2 seen after treatment of MCF-7 cells with steroidal antiestrogens. The loss of ER and down-regulation of progesterone receptor under treatment with the steroidal antiestrogens is prevented by OHT, whereas the steroidal antiestrogens prevent the ability of hydroxytamoxifen to increase the ER content. These results indicate that TGF-ß2 is a marker of action for both types of compounds, but steroidal and nonsteroidal antiestrogens partially antagonize each other in blocking ER-mediated cellular events. It would appear that no additive or synergistic effect of the two types of antiestrogens can be expected in the treatment of breast cancer.

¹ This work was supported by a Grant 70-1885-Kn-1 from the Deutsche Krebshilfe (to C. K.).

² To whom requests for reprints should be addressed, at Department of Clinical Chemistry, University Hospital Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.

Received 7/ 7/97. Accepted 11/13/97.

This article has been cited by other articles:

				R. C. Hovey, M. Asai-Sato, A. Warri, B. Terry-Koroma, N. Colyn, E. Ginsburg, and B. K. Vonderhaar Effects of Neonatal Exposure to Diethylstilbestrol, Tamoxifen, and Toremifene on the BALB/c Mouse Mammary Gland Biol Reprod, February 1, 2005; 72(2): 423 - 435. [Abstract] [Full Text] [PDF]

				M. B. Buck, K. Pfizenmaier, and C. Knabbe Antiestrogens Induce Growth Inhibition by Sequential Activation of p38 Mitogen-Activated Protein Kinase and Transforming Growth Factor-{beta} Pathways in Human Breast Cancer Cells Mol. Endocrinol., July 1, 2004; 18(7): 1643 - 1657. [Abstract] [Full Text] [PDF]

				M. B. Buck, P. Fritz, J. Dippon, G. Zugmaier, and C. Knabbe Prognostic Significance of Transforming Growth Factor {beta} Receptor II in Estrogen Receptor-Negative Breast Cancer Patients Clin. Cancer Res., January 15, 2004; 10(2): 491 - 498. [Abstract] [Full Text] [PDF]

				A. S. Jakate, C. M. Einhaus, A. P. DeAnglis, G. S. Retzinger, and P. B. Desai Preparation, Characterization, and Preliminary Application of Fibrinogen-Coated Olive Oil Droplets for the Targeted Delivery of Docetaxel to Solid Malignancies Cancer Res., November 1, 2003; 63(21): 7314 - 7320. [Abstract] [Full Text] [PDF]

				V. Marsaud, A. Gougelet, S. Maillard, and J.-M. Renoir Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor {alpha} (ER{alpha}), Differentially Affect ER{alpha} Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells Mol. Endocrinol., October 1, 2003; 17(10): 2013 - 2027. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]